drugset / Trial / NCT01493245

A Study of JNS020QD in Patients With Chronic Pain

NCT01493245

Phase 3 Completed 77 enrolled Janssen Pharmaceutical K.K.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of JNS020QD in patients with moderate to severe chronic pain who switched from opioid analgesics, as well as the safety and efficacy of long-term treatment (52 weeks) after switching to JNS020QD.

Timeline

Start
2011-10
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Fentanyl Other / unclassified Topical

Indications